CN104352501A - Compound ceftiofur sodium injection - Google Patents
Compound ceftiofur sodium injection Download PDFInfo
- Publication number
- CN104352501A CN104352501A CN201410627883.9A CN201410627883A CN104352501A CN 104352501 A CN104352501 A CN 104352501A CN 201410627883 A CN201410627883 A CN 201410627883A CN 104352501 A CN104352501 A CN 104352501A
- Authority
- CN
- China
- Prior art keywords
- injection
- ceftiofur sodium
- parts
- sodium
- magnolol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a compound ceftiofur sodium injection with significant antibacterial action. The compound ceftiofur sodium injection comprises the following components in parts by weight: 1-4 parts of ceftiofur sodium, 1-2 parts of magnolol, 0.5-1 part of sodium sulfite, 0.5-1 part of glycine and 1-2 parts of Tween. The injection disclosed by the invention is high in stability and simple in preparation process, has a good inhibiting effect on swine escherichia coli, has an accurate curative effect on porcine colibacillosis, is capable of reducing the dosage of a prescribed preparation and shortening the treatment cycle, and has a wide market prospect.
Description
Technical field
The present invention relates to a kind of compound preparation of beta-lactam antibiotic, particularly relate to a kind of injection of ceftiofur sodium honokiol.
Background technology
Colibacillosis of pigs is the piglet one group of enteric infection disease caused by pathogenic Escherichia coli.Common are yellow scour of piglet, piglet pujos blancos and baby pig edema three kinds, there is enteritis, enterotoxemia for feature.Pig yellow scours is again early onset colibacillosis, is that the one of the newborn piglet caused by the escherichia coli of certain serotype is acute, lethal infectious diseases.Mainly piglet morbidity within life age in days of rear a few hours to 5, the most common with 1-3 age in days.Pig Hakuri is also known as Delayed onset colibacillosis.The piglet of main infection 10-30 age in days.Generation is had on a lot of pig farm of China.Bowel oedema disease is a kind of acute fatal disease that the toxin having hemolytic relative gene amount reproduction to produce causes.Mainly betide the piglet before and after wean.Suddenly, the course of disease is short in morbidity, and dead fast, mortality rate is high.
Escherichia coli endotoxin is the lipopolysaccharide contained in escherichia coli adventitia, is released when thalline disintegrate, and lipoid A composition wherein has endotoxic biological function, is a kind of virulence factor, acts on particularly evident in septicemia.Escherichia coli extracellular toxin divides two large classes, and the first kind is heat-labile toxin (LT) and heat-stable toxin (ST).LT has antigenicity, and molecular weight is large, and 60 degree were destroyed through 10 minutes, can activate the epithelial adenosine cyclase of intestinal blood capillary.Increase cyclic adenosine monophosphate (cAMP) to produce, make intestinal mucosa cells hypersecretion, diarrhoea and dehydration occur; And ST can activate the guanylcyclase of the graininess on ileal epithelium brushing hair, increase cGMP and produce, cause secretory diarrhea equally.
At present this disease is mainly contained to the immunity of vaccine, the modes such as antibiotic, chemicals, Chinese medicine carry out prevention and therapy.Wherein vaccine immunization, because of enteric microorganism antigen and antigenic determinant complexity, immunologic mechanism is difference slightly, and immune effect is imprecise.Along with antibacterials abuse clinically, cause the drug resistance of the antibacterials such as escherichia coli very general, as the curative effect of medication such as gentamycin, oxytetracycline, norfloxacin, norfloxacin conventional clinically reduces.Prevent with other, Therapeutic Method compares, Chinese herbal medicine has non-specific antimicrobial effect, and residual toxicity is lower, and animal generally not easily produces drug resistance to it.And Chinese medicine and Western medicine are carried out effective compatibility, the generation of Resistant strain can be slowed down.
Summary of the invention
The invention provides a kind of injection comprising ceftiofur sodium honokiol with synergetic antibacterial effect, there is good therapeutical effect to colibacillosis of pigs, greatly reduce the consumption of single preparations of ephedrine, good stability, not drug resistance, overcomes the deficiencies in the prior art part.
Technical scheme of the present invention is: a kind of compound ceftiofur sodium injection, it is characterized in that the parts by weight of each component in described compositions are: ceftiofur sodium 1-4 weight portion; Magnolol 1-2 weight portion; Sodium sulfite 0.5-1 weight portion; Glycine 0.5-1 weight portion; Tween 1-2 weight portion.The weight ratio of ceftiofur sodium honokiol is 1:1 or 2:1.Tween is selected from Tween 80 or polysorbas20.
Compared with the prior art, injection of injection ceftiofur sodium honokiol provided by the invention and preparation method thereof, has the following advantages:
1, the compound injection good stability of ceftiofur sodium honokiol provided by the invention.
2, antibacterial activity is high: in the present invention, ceftiofur sodium honokiol coordinates with specific ratio, can produce cooperative effect, when reducing dosage, farthest plays Antifungal activity.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment.
Embodiment 1
Ceftiofur sodium, glycine are added successively in 300ml water for injection; By tween, sodium sulfite is dissolved in 400ml water for injection, slowly adds magnolol to dissolving completely under stirring; Merge two parts of solution, mend and inject water to 1000ml, add active carbon and stir, filter, sterilizing, fill.
Embodiment 2
Ceftiofur sodium, glycine are added successively in 300ml water for injection; By tween, sodium sulfite is dissolved in 400ml water for injection, slowly adds magnolol to dissolving completely under stirring; Merge two parts of solution, mend and inject water to 1000ml, add active carbon and stir, filter, sterilizing, fill.
Embodiment 3
Ceftiofur sodium, glycine are added successively in 300ml water for injection; By tween, sodium sulfite is dissolved in 400ml water for injection, slowly adds magnolol to dissolving completely under stirring; Merge two parts of solution, mend and inject water to 1000ml, add active carbon and stir, filter, sterilizing, fill.
Embodiment 4
Pharmacological evaluation: different ratio ceftiofur sodium and magnolol in vitro activity
Materials and methods
1. test proportioning: following proportions by weight.
(1) ceftiofur sodium
(2) magnolol
(2) ceftiofur sodium+magnolol (1: 1)
(3) ceftiofur sodium+magnolol (2: 1)
(4) ceftiofur sodium+magnolol (4: 1)
(5) ceftiofur sodium+magnolol (8: 1)
2. test strain:
Minimum inhibitory concentration (MIC) measures
Adopt meat soup trace doubling dilution, magnolol and cefmetazole being diluted with sterilizing M-H meat soup is the medicinal liquid of a series of concentration.Getting 100 μ l respectively adds in micro-hole, adds certain density bacterial suspension afterwards, makes final every hole concentration be 1.5 × 10
5cFU/ml, antibacterial application liquid concentration is 37 DEG C of incubated overnight.Minimum antibiotic concentration without bacterial growth is minimum inhibitory concentration (MIC, mg/L).Result of the test is as following table:
As can be seen from the MIC data in upper table, the compound preparation that ceftiofur sodium honokiol is prepared according to a certain weight ratio is better than two kinds of folk prescription medicines far away to the inhibitory action of escherichia coli cvcc223, dosage reduces greatly, the compound preparation that both make can play antibacterial synergism, enhances antibacterial efficacy.
Clinical trial and observation of curative effect
Test grouping: be divided into 5 groups at random by making a definite diagnosis the natural occurrence piglet 250 suffering from HUANGBAI(sic) dysentery.I, II, III group is trial drug ceftiofur sodium+magnolol (2: 1) high, medium and low treatment group, presses 0.05ml/Kg body weight, 0.03ml/Kg body weight, 0.01ml/Kg body weight drug administration by injection respectively, every day 2 times, is used in conjunction 3.IV group is ceftiofur sodium injection matched group, 0.1ml/Kg body weight, and intramuscular injection, is used in conjunction 3 days at every day 2 times.V group is magnolol matched group, and by 0.1ml/Kg body weight, intramuscular injection, every day 2 times, is used in conjunction 3 days.Each test group isolated rearing, intensive care.
Observation of curative effect: Continuous Observation 15 days after medication, each group of pig perfect compound feed of feeding (not containing any antibacterials), duration of test is noted observing defecation number of times and feces state.
Result of the test is added up: add up each group of mortality rate, effective percentage, cure rate during off-test
Curative effect judging standard:
Recovery from illness: after treatment, the spirit of affected pig, appetite recover normal, and feces be strip or graininess, anus is dry, contraction,
Without red and swollen, without rebound phenomenon in seven days.
Effective: feces retrogradation after treatment, defecation frequency reduces, and anus redness does not disappear completely, and spiritual appetite makes moderate progress.
Invalid: after treatment, affected pig spirit, feces, appetite are not improved, even dead.
Trial drug treatment colibacillosis of piglet statistical effect table
| Group | Sample number | Dead | Invalid | Effectively | Recovery from illness | Cure rate | Effective percentage |
| I | 50 | 0 | 0 | 50 | 48 | 96％ | 100％ |
| II | 50 | 0 | 0 | 50 | 48 | 96％ | 100％ |
| III | 50 | 0 | 0 | 50 | 47 | 94％ | 100％ |
| IV | 50 | 1 | 3 | 46 | 32 | 64％ | 92％ |
| V | 50 | 2 | 5 | 43 | 28 | 56％ | 86％ |
As seen from the above table, the compound injection of the high, normal, basic dosage of the present invention is with the obvious advantage relative to matched group on cure rate, even and if high dose, consumption is also lower than matched group.
Claims (4)
1. a compound ceftiofur sodium injection, is characterized in that the parts by weight of each component in described injection are: ceftiofur sodium 1-4 weight portion; Magnolol 1-2 weight portion; Sodium sulfite 0.5-1 weight portion; Glycine 0.5-1 weight portion; Tween 1-2 weight portion.
2. injection as claimed in claim 1, is characterized in that the weight ratio of described ceftiofur sodium honokiol is 1:1 or 2:1.
3. injection as claimed in claim 1 or 2, is characterized in that described tween is selected from Tween 80 or polysorbas20.
4. the purposes of the injection as described in claim arbitrary in claim 1-3 in the medicine of preparation treatment colibacillosis of pigs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410627883.9A CN104352501B (en) | 2014-11-10 | 2014-11-10 | A kind of compound ceftiofur sodium injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410627883.9A CN104352501B (en) | 2014-11-10 | 2014-11-10 | A kind of compound ceftiofur sodium injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104352501A true CN104352501A (en) | 2015-02-18 |
| CN104352501B CN104352501B (en) | 2016-06-01 |
Family
ID=52519875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410627883.9A Active CN104352501B (en) | 2014-11-10 | 2014-11-10 | A kind of compound ceftiofur sodium injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104352501B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107320466A (en) * | 2017-08-16 | 2017-11-07 | 吉林大学 | Medical application of the magnolol in the enzyme inhibitors of NDM 1 are prepared |
| CN107789357A (en) * | 2016-08-31 | 2018-03-13 | 瑞普（天津）生物药业有限公司 | A kind of animal compound Cefquinome sulfate breast injection and preparation method thereof |
| CN109908118A (en) * | 2019-04-29 | 2019-06-21 | 西南大学 | Magnolol and/or honokiol are improving the application in Gram-negative bacteria Antibiotic Sensitivity |
| WO2021068614A1 (en) * | 2019-10-06 | 2021-04-15 | 吉林大学 | Application of honokiol and magnolol in preparing mcr-1 enzyme inhibitor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813760A (en) * | 2005-12-12 | 2006-08-09 | 浙江升华拜克生物股份有限公司 | Ceftiofur-containing powder injection for beast |
| CN102106857A (en) * | 2009-12-29 | 2011-06-29 | 齐鲁动物保健品有限公司 | Compound ceftiofur sodium freeze-dried power injection used for injection |
| CN103536529A (en) * | 2013-10-30 | 2014-01-29 | 游锡火 | Ceftiofur-containing long-acting injection and preparation method |
-
2014
- 2014-11-10 CN CN201410627883.9A patent/CN104352501B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813760A (en) * | 2005-12-12 | 2006-08-09 | 浙江升华拜克生物股份有限公司 | Ceftiofur-containing powder injection for beast |
| CN102106857A (en) * | 2009-12-29 | 2011-06-29 | 齐鲁动物保健品有限公司 | Compound ceftiofur sodium freeze-dried power injection used for injection |
| CN103536529A (en) * | 2013-10-30 | 2014-01-29 | 游锡火 | Ceftiofur-containing long-acting injection and preparation method |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789357A (en) * | 2016-08-31 | 2018-03-13 | 瑞普（天津）生物药业有限公司 | A kind of animal compound Cefquinome sulfate breast injection and preparation method thereof |
| CN107320466A (en) * | 2017-08-16 | 2017-11-07 | 吉林大学 | Medical application of the magnolol in the enzyme inhibitors of NDM 1 are prepared |
| CN109908118A (en) * | 2019-04-29 | 2019-06-21 | 西南大学 | Magnolol and/or honokiol are improving the application in Gram-negative bacteria Antibiotic Sensitivity |
| WO2021068614A1 (en) * | 2019-10-06 | 2021-04-15 | 吉林大学 | Application of honokiol and magnolol in preparing mcr-1 enzyme inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104352501B (en) | 2016-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Merrifield et al. | Probiotic applications for rainbow trout (Oncorhynchus mykiss Walbaum) II. Effects on growth performance, feed utilization, intestinal microbiota and related health criteria postantibiotic treatment | |
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103989728A (en) | Acalypha australis L. and beta-lactam antibacterial medicine containing compound medicine for livestock and poultry | |
| CN104352501A (en) | Compound ceftiofur sodium injection | |
| CN103989725A (en) | Acalypha australis L. and amikacin containing compound medicine for livestock and poultry | |
| CN106074654A (en) | A kind of Chinese medicine composition for regulating intestinal canal Flora Disturbance and its production and use | |
| AU2019204496A1 (en) | Anti-diarrhea formulation which avoids antimicrobial resistance | |
| CN103989727A (en) | Acalypha australis L. and mequindox containing compound medicine for livestock and poultry | |
| CN101879172A (en) | Compound preparation of ceftiofur sodium | |
| Gouife et al. | Photobacterium damselae subsp. damselae in mariculture | |
| CN104352490A (en) | Compound amoxicillin sodium injection | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN104971124B (en) | A kind of new application of pharmaceutical composition | |
| CN104352500B (en) | A kind of sulfated compound cefquinome injection | |
| JP4809225B2 (en) | Compositions for veterinary and medical applications | |
| CN101874774A (en) | Suspension composition containing lysozyme and florfenicol and preparation method thereof | |
| CN106109667A (en) | A kind of Chinese medicine composition improving enteric flora disturbance and its production and use | |
| CN101757220A (en) | Injection for treating piglet bacillary dysentery and preparation method thereof | |
| CN101757069A (en) | Oral medical liquid for treating chicken mixed infection as well as preparation method and application thereof | |
| CN103919861B (en) | Compound percutaneous Emulsion of Chinese medicine and western medicine of preventing and treating colibacillosis of piglet and preparation method thereof | |
| CN1879736B (en) | Antibacterial Chinese medicinal composition for birds and preparation method thereof | |
| CN101129379A (en) | Anticoccidiosis pharmaceutical composition and method of preparing the same | |
| Kiarie et al. | Effect of products derived from hydrolysis of wheat and flaxseed non starch polysaccharides by carbohydrase enzymes on net absorption in enterotoxigenic Escherichia coli (K88) challenged piglet jejunal segments | |
| Tamirat et al. | Review on necrotic enteritis | |
| CN106860857A (en) | A kind of chinese-western medicine preparation for treating the yellowish-white dysentery of pig |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |